Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Dopamine agonists and the risk of valvular heart disease

Nature Clinical Practice Neurology volume 3, pages 426–427 (2007)Cite this article

boxed-textSchade R et al. (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356: 29–38

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pritchett AM et al. (2002) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77: 1280–1286

    Article  Google Scholar 

  2. Zadikoff C et al. (2006) Cardiac valvulopathy associated with pergolide use. Can J Neurol Sci 33: 27–33

    Article  Google Scholar 

  3. Connolly HM et al. (1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337: 581–588

    Article  CAS  Google Scholar 

  4. Hofmann C et al. (2006) Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol 29: 80–86

    Article  CAS  Google Scholar 

  5. Dewey RB Jr et al. (2007) Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease. Arch Neurol 64: 377–380

    Article  Google Scholar 

  6. Zanettini R et al. (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356: 39–46

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Helen Jacques, Editorial Assistant, Nature Clinical Practice.

Author information

Author notes

  1. Movement Disorders Clinic, Glenrose Rehabilitation Hospital, 10230—111 Avenue, Edmonton, Alberta T5G 0B7, Canada wayne.martin@ualberta.ca

Authors and Affiliations

  1. WRW Martin is a Professor in the Division of Neurology at the University of Alberta, Edmonton, AB, Canada.,

    WR Wayne Martin

Authors
  1. WR Wayne Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Dr Martin participated in clinical trials funded by Boehringer Ingelheim, Kyowa, Novartis, Schwarz and Teva.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martin, W. Dopamine agonists and the risk of valvular heart disease. Nat Rev Neurol 3, 426–427 (2007). https://doi.org/10.1038/ncpneuro0534

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0534

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing